Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
- 1 March 2008
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (3) , 471-472
Abstract
Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin’s lymphoma (NHL).[1][1]–[3][2] Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5–10% of the patients and carries a dismal prognosis.[4][3],[5][4] Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.[6][5]–[8][6] We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies. [1]: #ref-1 [2]: #ref-3 [3]: #ref-4 [4]: #ref-5 [5]: #ref-6 [6]: #ref-8Keywords
This publication has 10 references indexed in Scilit:
- The role of FDG-PET scans in patients with lymphomaBlood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Hodgkin transformation of chronic lymphocytic leukemiaCancer, 2006
- Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptakeHematological Oncology, 2006
- Reliability of uptake estimates in FDG PET as a function of acquisition and processing protocols using the CPETIEEE Transactions on Nuclear Science, 2005
- Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Richter syndromeCancer, 2005
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003
- World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997Journal of Clinical Oncology, 1999